GCG and Hyperglycemia: We hypothesize that gedatolisib may not affect pancreatic islet cells, hepatocyte potency, or drug uptake sufficiently to trigger glucagon release, glycogenolysis, and gluconeogenesis that would, in turn, lead to sustained systemic hyperglycemia and/or hyperinsulinemia.